Two Smaller Biotechs Poised for VK2735 Phase 3, Obefazimod Q2 Catalysts
For investors who missed Eli Lilly’s rally, Viking Therapeutics is developing VK2735 with phase 3 weight-loss data expected by mid-2026, and Abivax plans to report maintenance study results for ulcerative colitis candidate obefazimod in Q2. Both plays carry high clinical risk but could drive significant stock moves on positive trials.
1. Viking Therapeutics Advances VK2735 Phase 3 Trial
Viking Therapeutics is enrolling patients in its phase 3 study of VK2735, a dual GLP-1/GIP receptor agonist designed to mimic weight-loss efficacy seen with established therapies. Topline data are anticipated by mid-2026 and could validate VK2735’s potential as a competitive alternative in the obesity market.
2. Abivax Schedules Q2 Maintenance Data for Obefazimod
Abivax is preparing to release results from its maintenance study of obefazimod in ulcerative colitis during Q2, targeting long-term remission through modulation of monocyte/macrophage pathways. Positive findings could position obefazimod as a differentiated therapy, but trial design and safety endpoints introduce execution risk.